Dogwood Therapeutics Inc. focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
